Acetaminophen Special Populations Toxicity Data Lacking, NDAC Says
This article was originally published in The Tan Sheet
Executive Summary
There are insufficient data on special populations or disease states to warrant acetaminophen label changes to warn such individuals they may be at increased risk for hepatotoxicity, FDA's Nonprescription Drugs Advisory Committee concluded Sept. 19
You may also be interested in...
Acetaminophen “Black Box” Warning Would “Scare” Users, NDAC Rep Says
Use of a "black box" warning on OTC acetaminophen labeling would be an inappropriate means for alerting consumers about potential liver damage, two consultants to FDA's Nonprescription Drugs Advisory Committee said Sept. 19
Acetaminophen “Black Box” Warning Would “Scare” Users, NDAC Rep Says
Use of a "black box" warning on OTC acetaminophen labeling would be an inappropriate means for alerting consumers about potential liver damage, two consultants to FDA's Nonprescription Drugs Advisory Committee said Sept. 19
Acetaminophen “Black Box” Warning Would “Scare” Users, NDAC Rep Says
Use of a "black box" warning on OTC acetaminophen labeling would be an inappropriate means for alerting consumers about potential liver damage, two consultants to FDA's Nonprescription Drugs Advisory Committee said Sept. 19